Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models

Caterina Camodeca, Elisa Nuti, Livia Tepshi, Silvia Boero, Tiziano Tuccinardi, Enrico A. Stura, Alessandro Poggi, Maria Raffaella Zocchi, Armando Rossello

Research output: Contribution to journalArticle

Abstract

Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalEuropean Journal of Medicinal Chemistry
Volume111
DOIs
Publication statusPublished - Mar 23 2016

Fingerprint

Disintegrins
Metalloproteases
Hodgkin Disease
Ligands
Matrix Metalloproteinases
Cells
Thiazolidines
Western World
Molecular modeling
X ray crystallography
X Ray Crystallography
Tumors
Young Adult
Lymphoma
Derivatives
Cell Line
Neoplasms
ADAM17 Protein

Keywords

  • ADAM-10 inhibitors
  • Hodgkin's lymphoma
  • NKG2D-L
  • Sulfonamido-based hydroxamates

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. / Camodeca, Caterina; Nuti, Elisa; Tepshi, Livia; Boero, Silvia; Tuccinardi, Tiziano; Stura, Enrico A.; Poggi, Alessandro; Zocchi, Maria Raffaella; Rossello, Armando.

In: European Journal of Medicinal Chemistry, Vol. 111, 23.03.2016, p. 193-201.

Research output: Contribution to journalArticle

@article{1bcbbc9699394c078bf39f2718d3abb8,
title = "Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models",
abstract = "Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.",
keywords = "ADAM-10 inhibitors, Hodgkin's lymphoma, NKG2D-L, Sulfonamido-based hydroxamates",
author = "Caterina Camodeca and Elisa Nuti and Livia Tepshi and Silvia Boero and Tiziano Tuccinardi and Stura, {Enrico A.} and Alessandro Poggi and Zocchi, {Maria Raffaella} and Armando Rossello",
year = "2016",
month = "3",
day = "23",
doi = "10.1016/j.ejmech.2016.01.053",
language = "English",
volume = "111",
pages = "193--201",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models

AU - Camodeca, Caterina

AU - Nuti, Elisa

AU - Tepshi, Livia

AU - Boero, Silvia

AU - Tuccinardi, Tiziano

AU - Stura, Enrico A.

AU - Poggi, Alessandro

AU - Zocchi, Maria Raffaella

AU - Rossello, Armando

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.

AB - Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.

KW - ADAM-10 inhibitors

KW - Hodgkin's lymphoma

KW - NKG2D-L

KW - Sulfonamido-based hydroxamates

UR - http://www.scopus.com/inward/record.url?scp=84957547562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957547562&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2016.01.053

DO - 10.1016/j.ejmech.2016.01.053

M3 - Article

VL - 111

SP - 193

EP - 201

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -